TLT demonstrates the powerful ability of Sapphire sensor to determine localised arterial blood pressure
14 March 2013. TLT has
released the first output results of its new pivotal scoping phase
study of the Sapphire optoelectronic blood pressure sensor. The
company has published videos demonstrating the unique power of the TLT
Sapphire Sensor to determine arterial blood pressures at different
points across the body. TLT also validated the sensor readings against
the gold standard (including the auscultatory manometer) blood
pressure measurement technique, as an example, for the carotid artery
measurement, proving the TLT Sapphire sensor to be highly accurate.
Commenting on this world-leading development, CEO Dr Sandeep Shah said, “This is a key and remarkable milestone in the history of TLT and also in the history of Medicine and medical sensors. As is easily seen from the videos, the TLT Sapphire sensor can, for example, deliver carotid, subclavian, temporal, deep ulnar arterial blood pressures, as well as radial pressures, all beat-to-beat and within just seconds of application. No other technology in the world can do this! This remarkable achievement now positions the TLT technology to become dominant not just in Cardiovascular Medicine but also in many other significant and valuable medical markets.”
See the videos below and on the video page >>.
Tarilian Laser Technologies Ltd (TLT) is a UK company dedicated to the development and commercialisation of a novel optoelectronic sensor technology that has unique and powerful applications in medicine and also other industrial applications.
The unique sensor offers a superior bandwidth and capability beyond all other technologies for blood pressure measurement and cardiovascular profiling.
The sensor is also economical to produce and easily scalable to mass manufacture.
TLT has thus broken a major barrier in medicine and sensor technology; and has developed a powerful product family.
TTLT's Dr Sandeep Shah presents at the UKTI Global Business Summit, chaired by Sir Mark Walport, Director of the Wellcome Trust.